COMMUNIQUÉS West-GlobeNewswire

Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
03/03/2026
Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader [...]
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
03/03/2026
NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs [...]
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
03/03/2026
Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money. RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a [...]
Prenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million
03/03/2026
- CEO Danny Yeung makes personal investment in this round of approximately $750,000, up from investment of approximately $502,000 in November 2025 NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited ( [...]
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
03/03/2026
Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven liquid biopsy tests [...]
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
03/03/2026
Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients’ continued treatment burden and unmet needs CAMBRIDGE, Mass [...]
Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
03/03/2026
Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains 53% of people surveyed rank sleep as the most important behavior for a long, healthy life, ahead [...]
SHERPA research consortium initiates seven clinical studies to validate AI-based assistive technologies for minimally invasive brain and cancer treatments
03/03/2026
March 3, 2026 With a total budget of EUR 21.5 million, the four-year SHERPA research project is coordinated by Philips and co-funded by the EU Innovative Health Initiative (IHI) and industry partners The project focuses [...]
Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval
03/03/2026
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating its autologous CAR-Treg therapy, QEL-005, in patients with Rheumatoid [...]
Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant Study
03/03/2026
London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today shared interim top- [...]
Montis Biosciences Advances First-in-Class Dual-Action C1q Antibody with Strong Preclinical Proof-of-Concept in Neuroinflammatory Diseases
03/03/2026
Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammation MB0109 demonstrated statistically [...]
SNIPR announces Publication of Final Positive Phase 1 Results for SNIPR001 in The Lancet Microbe
03/03/2026
First-ever randomized, placebo-controlled Phase 1 trial - published in The Lancet Microbe - supports SNIPR001’s safety, tolerability, and restriction to the gastrointestinal tract in healthy participants Oral SNIPR001 [...]
Fagron completes acquisition of Vepakum
03/03/2026
Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 3 March 2026 – 7:00AM Fagron completes acquisition of Vepakum Fagron, the leading global player in pharmaceutical compounding, [...]
AEON Clinic Introduces Exomind to Treat OCD ADHD PTSD And Other Complex Mental Health Conditions
03/03/2026
The Future of Mental Sovereignty: AEON Clinic Launch EXOMIND™ at Atlantis The Royal DUBAI, United Arab Emirates, March 03, 2026 (GLOBE NEWSWIRE) -- AEON Clinic, a top pioneer in regenerative medicine and opulent [...]
Care@Home 4 Life Announces the Appointment of Industry Veteran Daniel Peters as Regional Sales Director
03/03/2026
Peters brings over 15 years of senior care and financial expertise to advance Care@Home 4 Life's mission of keeping seniors safely in the homes they love. Miami, FL, March 02, 2026 (GLOBE NEWSWIRE) -- Care@Home 4 Life [...]
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock
03/03/2026
Financing included participation by healthcare-dedicated investors alongside existing shareholders CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company [...]
BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
03/03/2026
LOUISVILLE, Ky., March 02, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex [...]
Alignment Healthcare Announces Pricing of Secondary Offering
03/03/2026
ORANGE, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) (“Alignment Healthcare” or the “Company”), an award-winning Medicare Advantage (MA) company, today announced the pricing of [...]
Myriad Commercially Launches Precise MRD with Select Community Oncologists
02/03/2026
Launch Represents Significant Step to Broader Commercialization SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, [...]

Pages